D. Ross Camidge, MD, PhD

Articles

Patient Prioritization Is the Foundation for a Successful Neurologic Oncology Career: With D. Ross Camidge, MD, PhD; and Douglas Ney, MD

October 23rd 2024

Drs Camidge and Ney discuss Dr Ney’s journey to becoming a neurologic oncologist and his experience as a physician with Tourette syndrome.

FDA Involvement in Dose Optimization Through Project Optimus Drives a Patient-Focused Oncology Pharmacology Career: With D. Ross Camidge, MD, PhD; and Jeanne Fourie Zirkelbach, PhD

October 9th 2024

Drs Camidge and Zirkelbach discuss Zirkelbach's first pharmacokinetics forays and her involvement with reforming dose optimization in drug development.

Camidge and Wilfong on Making A Difference Through a Career in Continuing Medical Education

September 12th 2024

D. Ross Camidge, MD, PhD, and Kadrin Wilfong, MD discuss Wilfong's passion for continuing medical education (CME) and how CME events and resources can make a difference in the care of patients with cancer.

Camidge and Kahl Reflect on the Impact of Oncology Journalism

July 22nd 2024

Camidge and Kahl reflect on the steps in Kahl’s communications career that paved the way for her to become a leader in the medical journalism field.

Camidge and White on Crucial Aspects of Patient-Focused Oncology Communication

July 4th 2024

Camidge and White discuss the intersections between White’s head and neck cancer diagnosis and radiation oncology communications career.

Camidge and Cooper on Finding Purpose and Embracing Nuance in Hospital Chaplaincy

June 13th 2024

Camidge and Cooper discuss Cooper’s career as a hospital chaplain, the focus of her writing, and the importance of meeting patients where they are.

Key Takeaways in HER2-Mutated NSCLC

May 29th 2024

The panel concludes the discussion with key takeaways on the evolving treatment landscape in HER2 non–small cell lung cancer.

Treatment Considerations in HER2-Mutated NSCLC

May 29th 2024

Experts on HER2 NSCLC provide clinical insights on selecting between antibody-drug conjugates and TKIs, treatment sequencing, and the role of chemoimmunotherapy.

Camidge and Datta Detail the Career of an “Opportunistic Nomad”

May 27th 2024

Drs Camidge and Datta highlight Dr Datta’s career as a surgeon-scientist and research that aims to improve systemic therapies for pancreatic cancer.

Challenges and Unmet Needs in HER2-Mutated NSCLC

May 22nd 2024

The expert panel shares its thoughts on current challenges and unmet needs in the overall HER2-mutated non–small cell lung cancer treatment landscape.

Adverse Events Associated With TKIs in HER2-Mutated NSCLC

May 22nd 2024

D. Ross Camidge, MD, PhD, discusses the main adverse events seen with TKIs in patients with HER2-mutated non–small cell lung cancer.

Camidge and Arslan Calculate the “Impact Factor” of a Career in Medicine

May 16th 2024

Drs Camidge and Arslan discuss Dr Arslan’s experience providing emergency medical care and the curiosity that led him to pursue a career in industry.

First-in-Human Study of BAY2927088 in Advanced HER2-Mutated NSCLC

May 15th 2024

Martin Dietrich, MD, PhD, provides an overview of the first-in-human study of BAY2927088, a novel TKI, in patients with advanced HER2-mutated non–small cell lung cancer.

Beamion LUNG-1: Zongertinib in Advanced HER2-Mutated NSCLC

May 15th 2024

The panel offers comprehensive insights on the Beamion LUNG-1 clinical trial, which is investigating zongertinib in patients with advanced HER2-mutated non–small cell lung cancer.

The Potential Role of TKIs in HER2-Mutated NSCLC

May 8th 2024

Edward Kim, MD, MBA, describes the potential role of tyrosine kinase inhibitors (TKIs) in the treatment of patients with HER2-mutated non–small cell lung cancer.

Managing Adverse Events Associated With ADCs in HER2-Mutated NSCLC

May 8th 2024

Lyudmila A. Bazhenova, MD, an expert on non–small cell lung cancer, provides clinical insights on the management of adverse events associated with antibody-drug conjugates.

Efficacy With NRG1-Directed Agents in NSCLC

May 6th 2024

D. Ross Camidge, MD, PhD, of University of Colorado Health Lung Cancer Clinic – Anschutz Medical Campus, discusses clinical efficacy with agents targeted for NRG1-fusion–positive non–small cell lung cancer.

Ongoing Research Efforts Targeting NRG1 in Lung Cancer

May 6th 2024

D. Ross Camidge, MD, PhD, of University of Colorado Health Lung Cancer Clinic – Anschutz Medical Campus, discusses ongoing research for patients with non–small cell lung cancer who harbor NRG1 fusions.

Standard Treatments for NRG1 Fusion+ NSCLC

May 6th 2024

D. Ross Camidge, MD, PhD, of University of Colorado Health Lung Cancer Clinic – Anschutz Medical Campus, discusses standard treatments for patients with non–small cell lung cancer who harbor NRG1 fusions.

DESTINY-Lung04: First-Line Trastuzumab Deruxtecan in HER2-Mutated NSCLC

May 1st 2024

Edward S. Kim, MD, MBA, discusses the DESTINY-Lung04 trial, a study evaluating trastuzumab deruxtecan as first-line treatment for patients with HER2-mutated NSCLC.